MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
Role of Plasma miRNA223 and High Mobility Group Box 1(HMGB1) as Predictors of Drug Resistant Epilepsy
1 other identifier
observational
90
0 countries
N/A
Brief Summary
Evaluation of the role of estimation of serum level of miRNAs223 and HMGB1in detection of patient with drug resistant epilepsy. Early detection of the prognosis might help in guiding patients for proper management and treatment strategy. This may open the door for new drug trials.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2022
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 22, 2022
CompletedFirst Posted
Study publicly available on registry
September 27, 2022
CompletedStudy Start
First participant enrolled
November 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2024
CompletedOctober 18, 2022
October 1, 2022
1.9 years
September 22, 2022
October 16, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
role of estimation of serum level of miRNAs223 and HMGB1in detection of patient with drug resistant epilepsy.
Early detection of being drug resistant epilepsy might help in guiding patients for proper management and treatment strategy.
2year
Study Arms (2)
Drug resistant epilepsy
failure to achieve sustained seizure freedom after adequate and well tolerated trials of two antiseizure medications
Medically controled epilepsy
seizure freedom for at least the last 6months) matched in sex and age.
Interventions
Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy
Eligibility Criteria
Drug resistant epilepsy defined as(failure to achieve sustained seizure freedom after adequate and well tolerated trials of two anti-seizure medications) Well controlled epilepsy defined as(seizure freedom for at least the last 6months) matched in sex and age.
You may qualify if:
- Patients diagnosed as drug resistant epilepsy .
- Control group: patients diagnosed as medically controlled epilepsy
You may not qualify if:
- Symptomatic epilepsy (vascular, tumor, post encephalitic, syndromic and febrile seizures).
- Alzheimers disease
- Parkinsons disease
- amyotrophic lateral sclerosis
- major depression disorder
- Non neurological criteria: tumors and cardiovascular
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant lecture
Study Record Dates
First Submitted
September 22, 2022
First Posted
September 27, 2022
Study Start
November 1, 2022
Primary Completion
October 1, 2024
Study Completion
November 1, 2024
Last Updated
October 18, 2022
Record last verified: 2022-10